Fri May 1, 2009 1:00 am (PDT)

Special Notice:

Penn State Phase II Crohn's Trial Needs Participants

Dr. Jill Smith, Professor of Gastroenterology at Pennsylvania State University's College of Medicine, has opened registrations for the first Phase II clinical trial of LDN at a US medical center.

According to the trial website, http://www.hmc.psu.edu/colorectal/res earch/naltrexone.htm:

"Participants will have a complete physical, blood work taken, keep symptom diaries, complete questionnaires and continue with follow-up for 4 months. Cost of medication, office visits, and blood work are paid by the study. This research has been approved by the Institutional Review Board, under FDA regulations, at Penn State's College of Medicine."

Based on the anecdotal reports from patients with Crohn's disease from past years, as well as the very positive outcomes of Professor Smith's initial, small, open-label trial of LDN in Crohn's disease, the results of this Phase II trial should confirm the potency and safety of LDN in the treatment of autoimmune disease.

The sooner the trial is able to enroll its requisite number of people with Crohn's disease, the sooner the trial will be completed and results published.

This, in turn, should interest other researchers in a host of possible clinical trials for the many uses of LDN, as well as help open the door to FDA approval.

If you know of people who have Crohn's disease and could participate in the Penn State trial, please refer them as soon as possible to coordinating nurse Sandra Bingaman, at 717-531-8108.

Thank you for taking action in this important matter.

LDN Website Editors